A Phase 1/2 Open-Label Study of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors (ASCENT-J02)
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Sacituzumab govitecan (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ASCENT-J02
- Sponsors Gilead Sciences
- 27 Mar 2024 Planned primary completion date changed from 1 Apr 2025 to 1 May 2026.
- 17 Aug 2023 Number of treatment arms has been changed from 7 to 9. HR+/HER2- Metastatic Breast Cancer and Metastatic Urothelial Cancer indications has been added.
- 17 Aug 2023 Planned number of patients changed from 61 to 143.